Literature DB >> 6198583

Preoperative "basal" chemotherapy in the management of cancer of the stomach.

F O Stephens, A W Johnson, P Crea.   

Abstract

Twenty-seven patients with infiltrating gastric carcinoma received chemotherapy as the first stage in management to reduce tumour extent and viability in preparation for subsequent surgery. All patients who had received no previous treatment for their cancers were included in the study, regardless of the type or extent of the primary gastric lesion; there was no patient selection. In 25 patients chemotherapy was administered by intra-arterial infusion, while in two patients it was given intravenously. Of 21 patients who underwent repeat gastroscopy before surgery, 11 (52%) showed endoscopic improvement. Gastric resection was carried out in 24 of the 27 patients. The perioperative mortality was 11% (three of 27 patients). Of the 27 patients, 14 were initially assessed as having advanced incurable lesions. Only two of these remain well and apparently free of tumour. The other 13 patients were considered to have resectable and potentially curable lesions at the time of referral. Of these, 11 remain well and apparently free of tumour between one and five years after diagnosis; the other two patients in this group died from postoperative complications.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6198583     DOI: 10.5694/j.1326-5377.1984.tb103943.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  2 in total

1.  Palliative superselective intra-arterial chemotherapy for advanced nonresectable gastric cancer.

Authors:  I B Shchepotin; V Chorny; J Hanfelt; S R Evans
Journal:  J Gastrointest Surg       Date:  1999 Jul-Aug       Impact factor: 3.452

2.  Neoadjuvant chemotherapy for high-grade advanced gastric cancer.

Authors:  Y Yonemura; T Sawa; K Kinoshita; N Matsuki; S Fushida; S Tanaka; S Ohoyama; T Takashima; H Kimura; T Kamata
Journal:  World J Surg       Date:  1993 Mar-Apr       Impact factor: 3.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.